

Washington State Pharmacy and Therapeutics Committee & Drug Utilization Review Board
Meeting by Zoom Webinar
Wednesday, February 28, 2024, 9 a.m. to 4 p.m.

Agenda		
Time	Topic	Presenter
9 a.m.	Welcome & Introductions Pharmacy & Therapeutics (P&T) Committee Convenes (Reviews drug classes for the WA PDL)	Kavita Chawla, Committee Chair
	P&T/DUR overview	Donna Sullivan
	ADHD – surveillance report <ul style="list-style-type: none"> • Stakeholder input* • Motion 	Shannon Robalino, DERP
	Anticoagulant – Archive <ul style="list-style-type: none"> • Stakeholder input* • Motion 	Andrea Vintro, DERP
	Antiplatelet - Archive <ul style="list-style-type: none"> • Stakeholder input* • Motion 	Andrea Vintro, DERP
	Statins - Archive <ul style="list-style-type: none"> • Stakeholder input* • Motion 	Andrea Vintro, DERP
	PSCK9s - Archive <ul style="list-style-type: none"> • Stakeholder input* • Motion 	Andrea Vintro, DERP
	Pharmacy & Therapeutics Committee Adjourns Drug Utilization Review (DUR) Board Convenes (Reviews drug classes for the Apple Health PDL)	Kavita Chawla, Committee Chair
	Apple Health Policy: <ul style="list-style-type: none"> • 21.40.60 Oncology Agents: Androgen Biosynthesis Inhibitors <ul style="list-style-type: none"> ○ Stakeholder input* ○ Motion 	Ryan Taketomo, HCA
	Apple Health Policy: <ul style="list-style-type: none"> • 44.60.30.AA Asthma and COPD Agents: Omalizumab (Xolair) <ul style="list-style-type: none"> ○ Stakeholder input* ○ Motion 	Marissa Tabile, HCA
	Apple Health Policy: <ul style="list-style-type: none"> • 30.19.20.AA Endocrine and Metabolic Agents: Teprosumab (Tepezza) <ul style="list-style-type: none"> ○ Stakeholder input* ○ Motion 	Luke Dearden, HCA

** Stakeholders will be allowed 3 minutes for comments.*
Committee discussion and motions will follow stakeholder comments.

The times noted are estimates and subject to change.

If you are a person with a disability and need a reasonable accommodation or have questions please call Nonye Connor at 360-725-2044.

	<p>Allergy</p> <ul style="list-style-type: none"> • Antihistamine - Corticosteroids Combinations <p>Antibiotics</p> <ul style="list-style-type: none"> • Aminoglycosides - Inhaled • Lincosamides - Injectable • Monobactams – Inhaled • Pleuromutilins <p>Anticoagulants</p> <ul style="list-style-type: none"> • Factor Xa and Thrombin Inhibitors – Oral <p>Bone Density Regulators</p> <ul style="list-style-type: none"> • Selective Estrogen Receptor Modulators (SERMS) • Sclerostin Inhibitors <p>Cardiovascular Agents</p> <ul style="list-style-type: none"> • Cardiac Myosin Inhibitors <p>Dermatologics</p> <ul style="list-style-type: none"> • Macrolide Immunosuppressants <p>Gout Agents</p> <ul style="list-style-type: none"> • Pegylated Uric Acid Enzymes <p>Neuromuscular Agents</p> <ul style="list-style-type: none"> • Spinal Muscular Atrophy Agents <p>All classes in this section:</p> <ul style="list-style-type: none"> • Stakeholder input* • Motion 	Umang Patel, Magellan
	<p>Antidiabetics</p> <ul style="list-style-type: none"> • Amylin Analogs • Anti-CD3 Antibodies • DPP4 Inhibitor / SGLT2 Inhibitor Combinations • DPP4 Inhibitor / TZD Combinations • DPP4 Inhibitors • GLP1 Agonist / Insulin Combinations • GLP1 Agonists • Insulin - Intermediate Acting • Insulin - Long Acting • Insulin - Pre-Mixed • Insulin - Rapid Acting • Insulin - Short Acting • SGLT2 Inhibitors <ul style="list-style-type: none"> ○ Stakeholder input* ○ Motion 	Umang Patel, Magellan
	<p>Antihemophilic Products</p> <ul style="list-style-type: none"> • Gene Therapy Agents <ul style="list-style-type: none"> ○ Stakeholder input* ○ Motion 	Umang Patel, Magellan
	<p>Antipsychotics / Antimanic Agents</p> <ul style="list-style-type: none"> • Antipsychotics - Alpha Agonists <p>Sleep Disorder Agents</p> <ul style="list-style-type: none"> • Non-Benzodiazepine • Orexin Receptor Antagonists • Selective Melatonin Receptor Agonists • Tricyclic Agents 	Umang Patel, Magellan

** Stakeholders will be allowed 3 minutes for comments.*

Committee discussion and motions will follow stakeholder comments.

The times noted are estimates and subject to change.

If you are a person with a disability and need a reasonable accommodation or have questions please call Nonye Connor at 360-725-2044.

	<ul style="list-style-type: none"> ○ Stakeholder input* ○ Motion 	
4 p.m.	Drug Utilization Review (DUR) Board Adjourns	Kavita Chawla, Committee Chair

For all Apple Health (Medicaid) questions:

1. Go to [HCA Support](#).
2. Click **Public**. You will need a SecureAccess Washington (SAW) account. ([View instructions for accessing SAW.](#))
3. Once you have logged into SAW, you will see the HCA Support portal.
4. Click **Make a Request**.
5. Click the **Apple Health Pharmacy** tile. This will take you to the online form.



** Stakeholders will be allowed 3 minutes for comments.
Committee discussion and motions will follow stakeholder comments.*

The times noted are estimates and subject to change.

If you are a person with a disability and need a reasonable accommodation or have questions please call Nonye Connor at 360-725-2044.